Home Innovation That Matters

Innovation That Matters

BCX4161, a Promising New Orally Administered Drug for the Rare and Genetic Disorder Hereditary Angioedema, Received Fast Track Status from the FDA

BioCryst Pharmaceuticals, Inc., a small pharmaceutical company headquartered in Durham, North Carolina announced on January 26 that one of the drugs in the company’s pipeline, BCX4161 has been granted fast track status by the FDA. BCX4161 is a novel and selective inhibitor of plasma kallikrein...

A Conversation with Carl Firth, CEO of ASLAN Pharmaceuticals

Since setting up in 2010, Singapore-based ASLAN Pharmaceuticals has shaken up drug development with its innovative, virtual approach to advancing therapeutic candidates. Fresh from winning the Red Herring Top 100 Asia Award 2013, ASLAN CEO Dr. Carl Firth spoke about the company’s model, drug...

Inside Perspectives on Gene Editing: An Interview with Cellectis CEO André Choulika

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). Based in New York City and Paris, the company is capitalizing on its 17 years of expertise in gene editing. Built on its flagship...

Inside Perspectives: Numerate Aims for Speedier Drug Development with Artificial Intelligence

One of the “hottest” new areas in drug development is the use of artificial intelligence (AI). In the same way that other industries have developed predictive software to make more precise and accurate decisions, many believe that the pharma industry will be particularly attracted to...

Inside Perspectives on Cancer Immunotherapy: An Interview with Juno CEO Hans Bishop

Juno Therapeutics President and CEO Hans Bishop leads one of the most dynamic, pioneering companies in the field of cancer immunotherapy. He describes this exciting, new strategy for destroying cancer cells as transformational, and he predicts it eventually will become the standard of care,...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

Cyclica CEO Naheed Kurji Says AI Could Create a New Paradigm...

Toronto-based Cyclica President and CEO Naheed Kurji acknowledges that artificial intelligence (AI) is a transformative technology, but he contends it is not the “silver...